drugset / Trial / NCT04810611
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.
Timeline
- Start
- 2021-06-18
- Primary completion
- 2024-04-19
- Completion
- 2024-04-19
Outcome
Outcome not reported
Stopped (Business): “Business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | — | — |
| Subject | NISEVOKITUG | Monoclonal antibody | — | — |
| Subject | Sabatolimab | Monoclonal antibody | — | — |